Health Care Compliance Association (HCCA)

Belkins
The Health Care Compliance Association (HCCA), established in 1996 and headquartered in Minneapolis, MN, is a non-profit professional membership organization made up of more than 11,700 compliance professionals working in the health care industry. HCCA offers over 50 training events a year, certification opportunities, and publications committed to improving the quality and recognition of the healthcare compliance industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

news image

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

MEDICAL

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

news image

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

PR.com | January 20, 2020

news image

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More

MEDICAL

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen | January 12, 2021

news image

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More

CELL AND GENE THERAPY

AbbVie | February 11, 2021

news image

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

MEDICAL

Recipharm | January 04, 2021

news image

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

PR.com | January 20, 2020

news image

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More

MEDICAL

AvantGen | January 12, 2021

news image

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More